次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

卵巣がん治療薬の世界市場2015-2025年

Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
Recently Approved Treatments Give High Market Potential

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年7月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文180ページになります。
商品コード:VGN434

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
卵巣がん治療薬の世界市場規模は2019年段階で17億1000万ドルに達すると推計され、2025年にかけて強力な拡大が見込まれます。 患者人口の増加、新薬の市場投入による売上拡大は市場の促進要因となるでしょう。
当レポートでは、2015年から2025年に至る卵巣がん治療薬の世界市場予測、セグメント別市場予測(化学療法、免疫療法、標的治療など)、主要製品別売上予測(Avastin、Lynparza、Yondelis)などの詳細予測データを掲載しています。さらに研究開発状況、リーディング製薬企業動向などの調査情報も織り交ぜ、概略以下の構成でお届けいたします。

【レポート構成概要】VGN434_Ovarian Cancer Drug Therapy Companies, R&D and Revenue Forecasts 2015-2025 Cover.jpg
◆卵巣がん治療薬の世界市場予測2015-2025年

◆セグメント別市場予測2015-2025、および分析
・化学療法
・標的治療
・免疫療法
・ホルモン治療

◆主要製品売上予測2015-2025、および分析
・Avastin (bevacizumab)
・Lynparza (olaparib).
・Yondelis (trabectedin).

◆主要11ヶ国、国別市場予測2015-2025、および分析
・米国
・日本
・ドイツ、フランス、英国、イタリア、スペイン
・ブラジル、ロシア、インド、中国

◆研究開発(R&D)の進展
・PARP阻害剤
・バイオ+化学療法
・腫瘍血管の破壊技術
・アンジオキナーゼ阻害剤
・ピロロベンゾジアゼピンに基づく細胞毒性技術
・黄体形成ホルモン放出ホルモン(LHRH)療法
・多価抗原-KLHコンジュゲートワクチン
・IL-12免疫療法
・キナーゼ阻害剤と抗血管新生療法
・モノクローナル抗体(mAbs)、がんワクチン
・卵巣がんの罹患率、患者人口の増加傾向
・後発医薬品との競合、政府当局による価格規制圧力
・提携、吸収合併など業界動向

◆卵巣がんのリーディング製薬企業動向
・Roche
・AstraZeneca
・Johnson & Johnson
・Zeltia
・Chugai.

◆業界企業オピニオンインタビュー3本
・Prima BioMed
・OXiGENE
・VBL Therapeutics.

◆調査結論
(全180ページ、114個のデータ表、グラフ類)
visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
Recently Approved Treatments Give High Market Potential

Table of Contents

1. Report Overview

1.1 Overview of the World Market for Ovarian Cancer Treatment
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Abbreviations Frequently Used in This Report

2. An Introduction to Ovarian Cancer Therapy

2.1 Overview of Ovarian Cancer
2.1.1 Symptoms of Ovarian Cancer
2.1.2 Risk Factors for Ovarian Cancer
2.1.3 Global Prevalence and Incidence of Ovarian Cancer
2.2 Diagnosing Ovarian Cancer
2.2.1 Laboratory Testing: The Uncertainty of CA 125 Testing
2.2.2 The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
2.2.3 Imaging Studies for Diagnosing Ovarian Cancer
2.3 Treatment Options for Cancer
2.3.1 Chemotherapy
2.3.2 Targeted Therapy
2.3.3 Immunotherapy: Fastest Growing Sector in Cancer Therapy
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Hormone Therapy
2.3.5 First-Line Therapy: Platinum-Taxane Treatment
2.3.6 Second-Line Therapy
2.3.7 Maintenance Therapy

3. Ovarian Cancer: World Market 2015-2025

3.1 Ovarian Cancer Therapies Market, 2014
3.1.1 A Note on Monoclonal Antibodies in this Report
3.2 Ovarian Cancer Therapies Market Forecast, 2015-2025
3.3 Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
3.3.1 Increasing Patient Population
3.3.2 Intense Competition from Generics
3.4 The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
3.5 The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.5.1 Targeted Therapy—Leading Submarket in Ovarian Cancer Therapy by 2025
3.5.2 Chemotherapy—Remains First-Line Treatment for Ovarian Cancer
3.5.3 Immunotherapy—The Fastest Growing Segment in Cancer Therapy
3.5.4 Hormone Therapy—Rare Treatment in Ovarian Cancer

4. Leading Ovarian Cancer Drugs 2014

4.1 Avastin (Roche/Chugai) – The World Market Leader
4.1.1 Avastin Revenue, 2010-2014 – Mixed Growth
4.1.2 Avastin Ovarian Cancer Forecast, 2015-2025
4.2 Lynparza (AstraZeneca)
4.2.1 Lynparza Forecast 2015-2025
4.3 Yondelis (Zeltia/Johnson & Johnson)
4.3.1 Yondelis (Zeltia/Johnson & Johnson): Historical Revenues
4.3.2 Yondelis Forecast 2015-2025
4.4 Other Ovarian Cancer Therapies

5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025

5.1 Regional Breakdown of the World Ovarian Cancer Therapeutics Market
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 The US Ovarian Cancer Drug Therapy Market, 2014
5.2.1 US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
5.3 The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
5.3.1 German Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.2 French Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.3 UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
5.3.3.1 NICE: Guidance for Ovarian Cancer Therapies
5.3.4 Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
5.3.5 Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.4 Japan: Growth in Generics - Ovarian Cancer Therapy Market Forecast, 2015-2025
5.5 Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
5.6 Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.7 Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
5.8 Russian Ovarian Cancer Therapy Market Forecast, 2015-2025

6. Leading Companies in the Ovarian Cancer Therapy Market

6.1 Companies with Exclusivity in 2014
6.2 Johnson & Johnson (J&J)
6.2.1 Sales and Performance Analysis, 2014
6.2.2 Pharmaceutical Segment Sales Analysis, 2014
6.2.2.1 R&D Performance Analysis, 2014
6.2.3 Recent M&A Activity: J&J Acquires Alios BioPharma and Aragon Pharmaceuticals
6.3 Roche
6.3.1 Sales and Performance Analysis, 2014
6.3.2 Pharmaceutical Segment Sales Analysis, 2014
6.3.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.3.2.2 Pharmaceutical Segment R&D Performance Analysis, 2014
6.3.3 Recent M&A Activity
6.4 AstraZeneca
6.4.1 Sales and Performance Analysis, 2014
6.4.2 Pharmaceutical Segment Sales Analysis, 2014
6.4.2.1 Cancer Drug Sales and Performance Analysis, 2014
6.4.2.2 R&D Performance Analysis, 2014
6.4.3 Recent M&A Activity: The Pfizer and AstraZeneca Saga

7. Ovarian Cancer Therapy: Developmental Pipelines 2015

7.1 Ovarian Cancer Phase III Candidates 2015
7.1.1 Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
7.1.1.1 TESARO and Merck to Collaborate: Niraparib and Keytruda
7.1.2 Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
7.1.3 Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
7.1.4 Recentin (AstraZeneca): Promising Results in Phase III
7.1.5 Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
7.1.6 Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
7.1.7 Binimetinib (Array Biopharma): Expected Filing in 2016
7.1.8 Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
7.1.9 Virgil (Gradalis): Autologous Tumour Cell Vaccine
7.1.10 Farletuzumab (Eisai): Failure in Phase III
7.2 Ovarian Cancer Phase II Candidates 2015
7.2.1 CVac (Prima BioMed): MUC-1 Cancer Vaccine
7.2.2 SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
7.2.3 Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
7.2.4 Reolysin (Oncolytics Biotech)
7.2.5 SGI110 (Astex Pharmaceuticals)
7.2.6 OvaRex (Quest PharmaTech)
7.2.7 Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
7.2.8 Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
7.2.9 Cyramza (Eli Lilly): Expanding Approved Indications
7.2.10 EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
7.2.11 Ganetespib and Elesclomol (Synta Pharmaceuticals)
7.2.12 ENMD-2076 (CASI Pharmaceuticals)
7.2.13 GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
7.2.14 Epacadostat (Incyte Corporation): IDO1 Inhibitor
7.2.15 AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
7.2.16 Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
7.2.17 Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
7.2.18 Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
7.2.19 Zybrestat (OXiGENE): Vascular Disrupting Agent
7.2.20 Yervoy (Bristol-Myers Squibb)
7.2.21 Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
7.2.22 Voxtalisib with Pimasertib (Sanofi and Merck Serono)
7.2.23 Eli Lilly’s Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab & Ralimetinib
7.2.24 MK2206 (Merck & Co.): AKT Inhibitor
7.2.25 A6 Peptide (Angstrom Pharma)
7.2.26 Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
7.3 Ovarian Cancer Phase II Candidates 2015
7.3.1 VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
7.3.2 MEDI4736 (AstraZeneca)
7.3.3 OVax (AVAX Technologies)
7.3.4 ME-344 (Novogen)
7.3.5 DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies

8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025

8.1 SWOT Analysis of the Ovarian Cancer Therapeutics Market
8.1.1 Strengths and Weaknesses of the Market
8.1.2 The Rising Incidence of Cancer
8.1.3 Drug Development Challenges
8.2 Opportunities and Threats for the Market
8.2.1 Advances in Research Open the Doors for Personalised Therapy
8.3 Regulations and Pricing Restrictions
8.4 STEP Analysis of the Ovarian Cancer Therapy Market
8.4.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.4.2 Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
8.4.3 Economic Factors: Cost Cutting in the EU and the US
8.4.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
8.5 Porter’s Five Forces Analysis of the Ovarian Cancer Therapeutics Market
8.5.1 Rivalry Among Competitors
8.5.2 Threat of New Entrants
8.5.3 Power of Suppliers
8.5.4 Power of Buyers
8.5.5 Threat of Substitutes

9. Research Interviews

9.1 Interview with Prof. Dror Harats, CEO, VBL Therapeutics
9.1.1 Outlook for VB-111 in the Ovarian Cancer Market
9.1.2 Drivers and Restraints in the Ovarian Cancer Market
9.1.3 Trends in the Ovarian Cancer Market
9.1.4 Outlook for VBL Therapeutics in the Oncology Market
9.2 Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
9.2.1 Outlook for CVac in the Ovarian Cancer Market
9.2.2 The Ovarian Cancer Market
9.2.3 Trends in the Ovarian Cancer Market
9.2.4 Outlook for Prima BioMed in the Oncology Market
9.3 Interview with a Representative of OXiGENE
9.3.1 Outlook for Zybrestat in the Ovarian Cancer Market
9.3.2 The Ovarian Cancer Market in 2015
9.3.3 Trends in the Ovarian Cancer Market, 2015-2025
9.3.4 Outlook for OXiGENE in the Oncology Market

10. Conclusions from the Research and Analysis

10.1 The World Ovarian Cancer Therapeutics Market in 2014
10.1.1 Leading National Markets to 2025
10.2 Trends in the Industry
10.2.1 Growing Interest in Personalised Therapy
10.2.2 Multiple Late-Stage Pipeline Drugs
10.3 Concluding Remarks

List of Tables

Table 1.1 Ovarian Cancer Therapy Market Forecast, 2014-2025
Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
Table 2.1 Types of Ovarian Cancer
Table 2.2 Stages of Ovarian Cancer
Table 2.3 Grades of Ovarian Cancer
Table 2.4 5-Year Prevalence for Ovarian Cancer by Region, 2012
Table 2.5 Incidence Rates for Ovarian Cancer by Country, 2012
Table 2.6 Cancer-Treating Agents: Chemotherapy, Immunotherapy, Targeted Therapy and Hormone Therapy, 2015
Table 3.1 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2014
Table 3.2 The World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.3 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2019 and 2025
Table 3.4 The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.5 Global Ovarian Cancer Targeted Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.6 Global Ovarian Cancer Chemotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.7 Global Ovarian Cancer Immunotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 3.8 Global Ovarian Cancer Hormone Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
Table 4.1 Avastin Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 4.2 Avastin Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 4.3 Lynparza Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 4.4 Yondelis Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 4.5 Yondelis Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.1 Ovarian Cancer Therapy Market: Revenue ($bn) and Market Share (%) by Country, 2014
Table 5.2 Ovarian Cancer Drug Therapy Market: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2015-2025
Table 5.3 Ovarian Cancer Therapy Revenue ($bn) and Market Share (%) by Country, 2014, 2019 and 2025
Table 5.4 US Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.5 EU5 Ovarian Cancer Drug Therapy Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.6 German Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.7 French Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.8 UK Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.9 Spanish Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.10 Italian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.11Japanese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.12 Chinese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.13 Indian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.14 Brazilian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 5.15 Ovarian Cancer Mortality Rate by Country, 2012
Table 5.16 Russian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Table 6.1 J&J Revenue ($bn) and Revenue Share (%) by Sector, 2014
Table 6.2 J&J Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.3 J&J: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Segment, 2013 and 2014
Table 6.4 J&J: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Table 6.5 Roche Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.6 Roche: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013 and 2014
Table 6.7 Roche: Anti-cancer Drug Revenues ($bn) and CAGR (%) by Therapeutic Area, 2012-2014
Table 6.8 Roche: Pharmaceutical R&D Expenses as a Percentage (%) of Company Revenue, 2012-2014
Table 6.9 Roche: Phase II Oncology Pipeline, 2015
Table 6.10 Roche: Phase III Oncology Pipeline, 2015
Table 6.11 AstraZeneca Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 6.12 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Therapeutic Area, 2013 and 2014
Table 6.13 AstraZeneca: Anti-cancer Drug Revenues ($bn) and CAGR (%), 2012-2014
Table 6.14 AstraZeneca: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Table 6.15 AstraZeneca: Ovarian Cancer R&D Pipeline, 2014
Table 7.1 Selected Late-Phase Pipeline Candidates for Ovarian Cancer, 2015
Table 7.2 Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015
Table 7.3 Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015 (Continued)
Table 7.4 Selected Early Phase Pipeline Candidates for Ovarian Cancer, 2015
Table 8.1 Strengths and Weaknesses of the Ovarian Cancer Therapy Market, 2015-2025
Table 8.2 Opportunities and Threats Facing the Ovarian Cancer Therapy Market, 2015-2025
Table 8.3 Social, Technological, Economic and Political Forces Influencing the Ovarian Cancer Therapy Market (STEP Analysis), 2015-2025

List of Figures

Figure 2.1 5-Years Prevalence for Ovarian Cancer by Region, 2012
Figure 2.2 Incidence Rates for Ovarian Cancer by Country, 2012
Figure 3.1 the World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
Figure 3.2 Ovarian Cancer Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.3 Ovarian Cancer Therapy Market by Therapeutic Class, 2019
Figure 3.4 Ovarian Cancer Therapy Market by Therapeutic Class, 2025
Figure 3.5 The Global Ovarian Cancer Therapy Market by Therapeutic Class: Revenue Forecasts ($bn), 2015-2025
Figure 3.6 Global Ovarian Cancer Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Ovarian Cancer Targeted Therapy Market: Drivers and Restraints, 2015-2025
Figure 3.8 Global Ovarian Cancer Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.9 Ovarian Cancer Chemotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.10 Global Ovarian Cancer Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.11 Ovarian Cancer Immunotherapy Market: Drivers and Restraints, 2015-2025
Figure 3.12 Global Ovarian Cancer Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
Figure 3.13 Ovarian Cancer Hormone Therapy Market: Drivers and Restraints, 2015-2025
Figure 4.1 Avastin Revenue ($bn) and AGR (%), 2010-2014
Figure 4.2 Avastin Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.3 Avastin: Drivers and Restraints, 2015-2025
Figure 4.4 Lynparza Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.5 Lynparza: Drivers and Restraints, 2015-2025
Figure 4.6 Yondelis Revenue ($bn) and AGR (%), 2010-2014
Figure 4.7 Yondelis Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
Figure 4.8 Yondelis: Drivers and Restraints, 2015-2025
Figure 5.1 Ovarian Cancer Drug Therapy Market Share (%) by Country, 2014
Figure 5.2 Developed National Markets: Drivers and Restraints, 2015-2025
Figure 5.3 Emerging National Markets: Drivers and Restraints, 2015-2025
Figure 5.4 Ovarian Cancer Therapy Market Share (%) by Country, 2019
Figure 5.5 Ovarian Cancer Therapy Market Share (%) by Country, 2025
Figure 5.6 US Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.7 EU5 Ovarian Cancer Therapy Markets: Revenue ($bn) Forecasts, 2015-2025
Figure 5.8 German Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.9 French Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.10 UK Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.11 Spanish Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.12 Italian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.13 Japanese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.14 Chinese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.15 Indian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.16 Brazilian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 5.17 Ovarian Cancer Mortality Rate by Country, 2012
Figure 5.18 Russian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
Figure 6.1 J&J Revenue Share (%) by Sector, 2014
Figure 6.2 J&J Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.3 J&J: Revenue Share (%) by Segment, 2014
Figure 6.4 J&J: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Figure 6.5 Roche Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.6 Roche: Pharmaceutical Revenue Share (%) by Segment, 2014
Figure 6.7 Roche: Anti-cancer Drug Revenue Share (%), 2014
Figure 6.8 Roche: Pharmaceutical R&D Expenses as a Percentage (%) of Company Revenue, 2012-2014
Figure 6.9 AstraZeneca Historical Revenue ($bn) and AGR (%), 2010-2014
Figure 6.10 AstraZeneca: Revenue ($bn) by Therapeutic Area, 2013 and 2014
Figure 6.11 AstraZeneca: Revenue Share (%) by Therapeutic Area, 2014
Figure 6.12 AstraZeneca: Anti-cancer Drugs Revenue Share (%) by Drug, 2014
Figure 6.13 AstraZeneca: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
Figure 8.1 Porter’s Five Forces Analysis of the Ovarian Cancer Drug Therapy Market, 2015-2025
Figure 10.1 Ovarian Cancer Therapy Market: Revenue Shares ($bn) by Drug, 2014-2025
Figure 10.2 Ovarian Cancer Therapy Market Revenue ($bn) by Country, 2014, 2019 and 2025

掲載企業リスト

Companies Listed

AbbVie
Actavis
Advaxis
Aeterna Zentaris
Alios BioPharma (part of J&J)
Almirall
American Cancer Society
American Society of Clinical Oncology
Amgen
Angstrom Pharma
Array BipPharma
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Australia and New Zealand Gynecological Oncology Group (ANZGOG)
Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)
Auven Therapeutics
AVAX Technologies
Baxter Healthcare
Boehringer Ingelheim
Bristol-Myers Squibb
Busto Arisizio Hospital [Italy]
Cancer Research Institute
Cancer Research UK
Cancer Treatment Centers of America
CASI Pharmaceuticals
Celgene
Cell Therapeutics
Celsion Corporation
Cerulean Pharma
Chiba University Hospital
Clovis Oncology
CTI BioPharma (formerly Cell Therapeutics)
Eisai
Eli Lilly
ENGOT
EntreMed (now CASI Pharmaceuticals)
European Commission (EC)
Expression Genetics
Facing Our Risk of Cancer Empowered (FORCE)
Food and Drug Administration [US]
Fox Chase Cancer Center
Fresenius Biotech North America
Galena Biopharma
GCIG
Genia (part of Roche)
Genentech
GlaxoSmithKline
Gradalis
Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Gynecologic Oncology Group
Immunovaccine
Immutep
Incyte
Indiana University School of Medicine
InterMune (part of Roche)
International Agency for Research on Cancer (IARC)
International Gynecologic Cancer Society (IGCS)
Janssen Biotech (part of Janssen Pharmaceutical Companies)
Janssen Pharmaceutical (part of J&J)
Janssen Products (part of Janssen Pharmaceutical Companies)
Jiangsu Hengrui Med
Johnson & Johnson (J&J)
Jubilant Biosys
Ludwig Institute for Cancer Research
MabVax Therapeutics
Marshall Edwards (now MEI Pharma)
Massachusetts General Hospital
McGill University
Medical Research Council [UK]
Medical University Innsbruck
MedImmune (part of AstraZeneca)
MEI Pharma (part of Novogen)
Memorial Sloan-Kettering Cancer Center
Menarini Group
Merck & Co.
Morphotek, Inc. (part of Eisai)
Myriad Genetics
National Cancer Institute [US]
National Health and Medical Research Council [Australia]
National Health Service (NHS) [UK]
NCIC Clinical Trials Group
National Institute for Health and Care Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
National Institutes of Health Clinical Center (NIHCC) [US]
Nektar Therapeutics
Neopharm Group
Nordic Society for Oncology
Novartis
Novogen
NRG Oncology
OBI Pharma
Oncolytics Biotech
Onconova Therapeutics
Orion Genomics
OXiGENE
Peter MacCallum Cancer Centre
PharmaMar (part of Zeltia Group)
Poniard Pharmaceuticals
Prima BioMed
Quest PharmaTech
Roche
Roxane
Sandoz (part of Novartis)
Sanofi
Santaris (part of Roche)
SCRI Development Innovations
Seragon Pharmaceuticals (part of Roche)
Society of Gynecologic Oncology
Spirogen
Stanford University
Sunesis Pharmaceuticals
Surveillance, Epidemiology and End Results Program (SEER) [US]
Synta Pharmaceuticals
Taiho Pharmaceutical
Takeda Pharmaceuticals
TESARO
University College London
University of Queensland’s Institute for Molecular Biosciences (IMB)
Vascular Biogenics Ltd (VBL Therapeutics)
VBL Therapeutics
VentiRx Pharmaceuticals
Westmead Millennium Institute for Medical Research
World Cancer Research Fund International
Worldwide Cancer Research
Zeltia Group
Zybrestat

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。